EACS 18. Europäische Aids Konferenz
London,  Oktober 2021

Die EACS Tagung findet in London und virtuell statt. Unter dem Motto „Crossing Borders“ werden alle relevanten Aspekte rund um HIV angesprochen. Die Studien zu neuen Medikamenten und die Aktualisierung der europäischen Leitlinien sind die Highlights der Konferenz.

https://eacs-conference2021.com/


Mehrklassenresistenz: Fostemsavir oder Ibalizumab?

Die beiden Substanzen sind zugelassen zur Behandlung von HIV-Positiven mit Multiresistenz und Therapieversagen. weiter

PrEP

In England durch PrEP 87% weniger HIV-Infektionen weiter




EACS 2021 Publikationen ViiV

DOLUTEGRAVIR

Switching to DTG/3TC is Non-inferior to Continuing Current Antiretroviral Regiment at Week 48: SALSA Subgroup Analyses
Taylor S.
Poster

View and download poster

Evaluating the Relationship Between Inflammation Biomarker Interleukin-6 (IL-6) Levels and Residual, Low-Level Viraemia in HIV-1 Suppressed Participants in the TANGO Study at Week 96
Wang R.
Poster

View and download poster

Switching to DTG/3TC is Non-inferior to Continuing a TAF-Based Regimen at Week 144: TANGO Subgroup Analyses
Scholten S.
Poster

View and download poster

Impact of Treatment Adherence on Efficacy of DTG + 3TC and DTG + TDF/FTC: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies
Fernvik E.
Poster

View and download poster

12-month outcomes of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany: Real-world data from the German URBAN cohort
Scholten S.
Poster

View and download poster

Two-year Outcomes of Dolutegravir/Rilpivirine in Virologically Suppressed HIV-infected PLHIV: Real-world Data from the German JUNGLE Cohort
Ummard-Berger K.
Poster

View and download poster

Durable Efficacy and Safety of DTG + 3TC in Treatment-Naive People With HIV-1 Stratified by Age: 144-Week Results From GEMINI-1 and -2
Spinelli F.
Poster

View and download poster

Incidence of hypertension in PLWH receiving InSTI versus other third drug ART regimens in the RESPOND cohort
Byonanebye DM. Poster

View and download poster

Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study
Mussini C.
Poster

View and download poster

CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment

Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB+RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
Hocqueloux L.
Poster

View and download poster

Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies
de los Rios P.
Poster

View and download poster

Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials
Eliot E.
Poster

View and download slides Slides with author audio

Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Health Care Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB+RPV LA) for People Living With HIV
Gutner C.
Poster

View and download slides

Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
Gutner C.
Poster

View and download poster

European Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes
Molina JM. Poster

View and download poster

Indirect Comparison of 96-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months Versus Dolutegravir/Abacavir/Lamivudine in Suppressed HIV-1 Infected Participants
Snedecor SJ. Poster

View and download poster

Outcomes for Participants During Long-term Follow-up After Discontinuation of Cabotegravir + Rilpivirine Long-Acting in the Phase III/IIIb Clinical Trials
Teichner P.
Oral

View and download slides Slides with author audio

FOSTEMSAVIR

Comparative Efficacy of Fostemsavir Versus Ibalizumab in Heavily Treatment-Experienced HIV Patients
Jacob I.
Poster

View and download poster

Long-term Inflammation Biomarker Changes With Fostemsavir in Heavily Treatment-Experienced Adults With HIV-1: Exploratory Analyses of the Phase 3 BRIGHTE Study
Clark A.
Poster

View and download poster

Emergent Resistance to Antiretroviral Agents Used in Optimized Background Therapy With Fostemsavir (FTR): Week 96 Results of the Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living With Multidrug-Resistant HIV-1
Gartland M.
Poster

View and download slides Slides with author audio

ABACAVIR

Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated People Living with HIV within the RESPOND Cohort Consortium
Jaschinski NJ. Poster

View and download slides

PLHIV PERSPECTIVES

Understanding the Perceived Therapeutic Need and Value Associated With Novel Long-Acting Antiretroviral Regimens Among People Living With HIV in 12 European Countries
Dakhia S.
Poster

View and download poster

DAIG LogoDGI LogoDSTIG LogoPEG Logo

Meldungen

  • Hepatitis E

    31. Juli 2025: Ribavirin-Dosierung bei Transplantierten weiter

  • HIV-Prävention

    31. Juli 2025: Einmalig Antikörper für Neugeborene? weiter

  • HPV

    30. Juli 2025: Beta-HPV kann bei Immunschwäche zu Hautkrebs führen weiter

  • HIV-PrEP

    28. Juli 2025: EMA-Zulassung für Lenacapavir zur PrEP weiter

  • COVID-19

    28. Juli 2025: Zulassungsempfehlung für neue Impfstoffe Comirnaty® und Spikevax® weiter

  • Newletter online

    Jeden Monat akutelle Informationen rund ums Thema HIV und sexuell übertragbare Erkrankungen.

    Für Ärzt_innen, Menschen mit HIV und alle Interessierten.

    Anmeldung hier

  • Antibiotika-Resistenz

    28. Juli 2025: Selbst im abgelegenen Antarktis-Ozean nachgewiesen weiter

  • Lenacapavir PrEP

    23. Juli 2025: Partnerschaft Gilead und Global Fund weiter

  • COVID-19

    23. Juli 2025: Consensus Statement zur Post-COVID Diagnostik bei Lungenveränderungen weiter

  • HTLV-1

    22. Juli 2025: Das Humane T-Zell Leukämie Virus Type 1 (HTLV-1) infiziert ähnlich wie HIV die Helferzellen. weiter

  • BK-Viren

    22. Juli 2025: Neue Strategien gegen Nierentransplantat-Verlust weiter

  • Hepatitis B

    22. Juli 2025: HepB-CpG Impfung schützt bei HIV-Infektion länger als herkömmlicher Impfstoff weiter

  • Hepatitis B

    22. Juli 2025: TherVacB-Projekt startet klinische Studie zur Heilung weiter

  • West-Nil-Virus

    21. Juli 2025: Todesfall in Italien weiter

  • Doxy-Pep/PrEP

    20. Juli 2025: Studie der Charité zu Kenntnissen, Einstellungen und Nutzungsverhalten weiter

  • Tetanus/Diphtherie

    15. Juli 2025: Booster-Impfung für Erwachsene unnötig? weiter

Ältere Meldungen weiter

Diese Website bietet aktuelle Informationen zu HIV/Aids sowie zur HIV/HCV-Koinfektion. Im Mittelpunkt stehen HIV-Test, Symptome und Auswirkungen der HIV-Infektion, Behandlung der HIV-Infektion, HIV-Medikamente mit Nebenwirkungen und Komplikationen, Aids, Hepatitis B und C. Ein Verzeichnis der Ärzte mit Schwerpunkt HIV ergänzt das Angebot.